Gong Xiaorui, Wang Xueying, Jin Jing, Gong Zhiqiang
Medical Oncology Department of Thoracic Cancer (II), Cancer Hospital of China Medical University Liaoning Cancer Hospital and Institute, Cancer Hospital of Dalian University of Technology, Shenyang, China.
Department of Child Healthcare, Shenyang Children's Hospital, Shenyang, China.
Front Immunol. 2025 Jun 18;16:1607225. doi: 10.3389/fimmu.2025.1607225. eCollection 2025.
Chemokines are key molecules that regulate immune cell migration and play critical roles in the tumor microenvironment. In lung cancer, chemokine dysregulation is closely linked to tumor progression. They promote immune cell infiltration and interact with tumor cells, enhancing tumor invasiveness and metastatic potential. This review highlights chemokine-mediated mechanisms, focusing on CCR9/CCL25 and CXCL12/CXCR4 axes, which promote tumor growth, metastasis, and immune evasion via PI3K/AKT and MAPK signaling. Elevated expression of these pathways correlates with poor outcomes and aggressive phenotypes. In SCLC, CXCR4 inhibitors show therapeutic promise when combined with chemotherapy or immunotherapy. This review summarizes the prognostic and therapeutic relevance of chemokines in lung cancer progression.
趋化因子是调节免疫细胞迁移的关键分子，在肿瘤微环境中发挥着至关重要的作用。在肺癌中，趋化因子失调与肿瘤进展密切相关。它们促进免疫细胞浸润并与肿瘤细胞相互作用，增强肿瘤的侵袭性和转移潜能。本综述重点介绍趋化因子介导的机制，着重于CCR9/CCL25和CXCL12/CXCR4轴，它们通过PI3K/AKT和MAPK信号通路促进肿瘤生长、转移和免疫逃逸。这些通路的高表达与不良预后和侵袭性表型相关。在小细胞肺癌中，CXCR4抑制剂与化疗或免疫疗法联合使用时显示出治疗前景。本综述总结了趋化因子在肺癌进展中的预后和治疗相关性。
